179 related articles for article (PubMed ID: 35338415)
1. Targeted Delivery of Endosomal Escape Peptides to Enhance Immunotoxin Potency and Anti-cancer Efficacy.
Polli JR; Chen P; Bordeau BM; Balthasar JP
AAPS J; 2022 Mar; 24(3):47. PubMed ID: 35338415
[TBL] [Abstract][Full Text] [Related]
2. Cell Penetrating Peptides Conjugated to Anti-Carcinoembryonic Antigen "Catch-and-Release" Monoclonal Antibodies Alter Plasma and Tissue Pharmacokinetics in Colorectal Cancer Xenograft Mice.
Polli JR; Balthasar JP
Bioconjug Chem; 2022 Aug; 33(8):1456-1466. PubMed ID: 35867869
[TBL] [Abstract][Full Text] [Related]
3. Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy.
Shin MC; Zhang J; Ah Min K; Lee K; Moon C; Balthasar JP; Yang VC
J Control Release; 2014 Nov; 194():197-210. PubMed ID: 25204286
[TBL] [Abstract][Full Text] [Related]
4. Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties.
Pirie CM; Hackel BJ; Rosenblum MG; Wittrup KD
J Biol Chem; 2011 Feb; 286(6):4165-72. PubMed ID: 21138845
[TBL] [Abstract][Full Text] [Related]
5. The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin.
Scott CF; Goldmacher VS; Lambert JM; Chari RV; Bolender S; Gauthier MN; Blättler WA
Cancer Immunol Immunother; 1987; 25(1):31-40. PubMed ID: 3496157
[TBL] [Abstract][Full Text] [Related]
6. Transient Inhibition of Trastuzumab-Tumor Binding to Overcome the "Binding-Site Barrier" and Improve the Efficacy of a Trastuzumab-Gelonin Immunotoxin.
Chen P; Bordeau BM; Zhang Y; Balthasar JP
Mol Cancer Ther; 2022 Oct; 21(10):1573-1582. PubMed ID: 35930739
[TBL] [Abstract][Full Text] [Related]
7. Targeted cytolysins synergistically potentiate cytoplasmic delivery of gelonin immunotoxin.
Pirie CM; Liu DV; Wittrup KD
Mol Cancer Ther; 2013 Sep; 12(9):1774-82. PubMed ID: 23832121
[TBL] [Abstract][Full Text] [Related]
8. "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibody Leads to Greater Plasma and Tumor Exposure in a Mouse Model of Colorectal Cancer.
Engler FA; Polli JR; Li T; An B; Otteneder M; Qu J; Balthasar JP
J Pharmacol Exp Ther; 2018 Jul; 366(1):205-219. PubMed ID: 29735609
[TBL] [Abstract][Full Text] [Related]
9. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD
J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356
[TBL] [Abstract][Full Text] [Related]
10. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.
Pagliaro LC; Liu B; Munker R; Andreeff M; Freireich EJ; Scheinberg DA; Rosenblum MG
Clin Cancer Res; 1998 Aug; 4(8):1971-6. PubMed ID: 9717827
[TBL] [Abstract][Full Text] [Related]
11. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.
Rosenblum MG; Marks JW; Cheung LH
Cancer Chemother Pharmacol; 1999; 44(4):343-8. PubMed ID: 10447583
[TBL] [Abstract][Full Text] [Related]
12. Antiviral immunotoxins: antibody-mediated delivery of gelonin inhibits Pichinde virus replication in vitro.
Barnett BB; Burns NJ; Park KJ; Dawson MI; Kende M; Sidwell RW
Antiviral Res; 1991 Feb; 15(2):125-38. PubMed ID: 1650165
[TBL] [Abstract][Full Text] [Related]
13. Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A chain conjugates.
Sivam G; Pearson JW; Bohn W; Oldham RK; Sadoff JC; Morgan AC
Cancer Res; 1987 Jun; 47(12):3169-73. PubMed ID: 3495329
[TBL] [Abstract][Full Text] [Related]
14. Photochemical internalisation increases the cytotoxic effect of the immunotoxin MOC31-gelonin.
Selbo PK; Sivam G; Fodstad O; Sandvig K; Berg K
Int J Cancer; 2000 Sep; 87(6):853-9. PubMed ID: 10956397
[TBL] [Abstract][Full Text] [Related]
15. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
[TBL] [Abstract][Full Text] [Related]
16. PTD-Modified ATTEMPTS for Enhanced Toxin-based Cancer Therapy: An In Vivo Proof-of-Concept Study.
Shin MC; Zhang J; Min KA; He H; David AE; Huang Y; Yang VC
Pharm Res; 2015 Aug; 32(8):2690-703. PubMed ID: 25701313
[TBL] [Abstract][Full Text] [Related]
17. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.
French RR; Penney CA; Browning AC; Stirpe F; George AJ; Glennie MJ
Br J Cancer; 1995 May; 71(5):986-94. PubMed ID: 7734325
[TBL] [Abstract][Full Text] [Related]
18. Targeting of type 1 ribosome-inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispecific antibodies.
Sforzini S; Bolognesi A; Meazza R; Marciano S; Tazzari PL; Stein H; Stirpe F; Ferrini S
J Hematother; 1995 Oct; 4(5):429-32. PubMed ID: 8581380
[TBL] [Abstract][Full Text] [Related]
19. A gelonin-containing immunotoxin directed against human breast carcinoma.
Rosenblum MG; Zuckerman JE; Marks JW; Rotbein J; Allen WR
Mol Biother; 1992 Sep; 4(3):122-9. PubMed ID: 1445665
[TBL] [Abstract][Full Text] [Related]
20. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
Griffin T; Raso V
Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
